Please login to the form below

Not currently logged in
Email:
Password:

Insmed

This page shows the latest Insmed news and features for those working in and with pharma, biotech and healthcare.

Features Archive listing

Insmed’s Olaf Bartsch tells PME about the US biotech’s year of progress. .

Latest news

  • Survival strategy

    Examples include Merck's $130m acquisition of Insmed's biologic facilities and pipeline, Mylan's deal with Biocon in 2009, Pfizer's $350m deal with Biocon for insulin biosimilars in October

  • Biogen Idec gains ALS drug

    In addition, under an FDA-approved programme, a limited number of people with ALS receive Insmed's Iplex, although the drug has not been granted marketing approval for the indication.

  • Biologics at forefront

    Novartis/Sandoz is already a major player in biosimilars while, last year, Merck acquired Insmed's portfolio of follow-on biologics for $130m in cash.

  • The Pump House

    Hepatitis. China. Mecasermin rinfabate. Iplex (Insmed). Growth disorders. US. Methylphenidate. Methylin Chewable Tablets (Alliant Pharmaceuticals).

More from news
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Significant figures Significant figures

    Significant figures. Insmed’s Olaf Bartsch tells PME about the US biotech’s year of progress. ... However, Insmed believes ALIS “has the opportunity to dramatically improve the treatment of NTM lung disease”.

  • Deal Watch October 2016 Deal Watch October 2016

    In the deal with Insmed the molecule is in phase I and has been licensed for development and commercialisation in an orphan indication to Insmed and AstraZeneca has retained the option ... 160. AstraZeneca (UK). Insmed. Licence. Dipeptidyl peptidase one

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics